Embecta CEO and diabetes advocates ring the opening bell at the NASDAQ

BD spinoff Embecta looks to build on 100 years of diabetes technology

[podcast src=”https://html5-player.libsyn.com/embed/episode/id/26409747/height/360/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/26a9e0/” width=”100%” scrolling=”no” class=”podcast-class” frameborder=”0″ placement=”top” primary_content_url=”http://traffic.libsyn.com/diabetesconnections/Ep_557_Final_Embecta_Dev.mp3″ libsyn_item_id=”26409747″ height=”360″ theme=”custom” custom_color=”26a9e0″ player_use_thumbnail=”use_thumbnail” use_download_link=”use_download_link” download_link_text=”Download” /]This week… one of the oldest diabetes companies is looking ahead – Once part of BD, makers of needles and syringes, Embecta is now working on new technology like a patch pump. I’m talking to CEO Dev Kurdikar about moving…